Metastatic renal cell carcinoma: How to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor

Future Oncology

Volumn 9, Issue 6, 2013, Pages 831-843

  Sabbatini, Roberto ^a   Ortega, Cinizia ^b   Procopio, Giuseppe ^c   Masini, Cristina ^a   Galligioni, Enzo ^d   Porta, Camillo ^e  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b CANDIOLO CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d SANTA CHIARA HOSPITAL   (Italy)

^e FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

metastatic; renal cell carcinoma; safety; tyrosine kinase inhibitor; VEGF

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ARTERIAL THROMBOEMBOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL DECISION MAKING; DIARRHEA; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY METASTASIS; LIVER FAILURE; LIVER TOXICITY; MEGALOCYTOSIS; META ANALYSIS (TOPIC); MORBIDITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PRIMARY HEALTH CARE; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT; SKIN MANIFESTATION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM;

CARCINOMA, RENAL CELL; DRUG DELIVERY SYSTEMS; DRUG TOXICITY; HUMANS; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 84878477265     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.58     Document Type: Review

References (63)

1. Patel C, Ahmed A, Ellsworth P. Renal cell carcinoma: a reappraisal. Urol. Nurs. 32(4), 182-190 (2012).
2. Ather MH, Masood N, Siddiqui T. Current management of advanced and metastatic renal cell carcinoma. Urol J. 7(1), 1-9 (2010).
3. Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest. 28, 312-322 (2010).
4. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat. Rev. 34, 193-205 (2008).
5. Shek D, Tomlinson B, Brown M, Brunson A, Pan C-X, Lara PN. Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28, 252 patients. Clin. Genitourin. Cancer 10(2), 93-98 (2012).
6. Escudier B, Osanto S, Ljungberg B et al. Multidisciplinary management of metastatic renal cell carcinoma in the era of targeted therapies. Cancer Treat. Rev. 38, 127-132 (2012).
7. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med. 7, 127-134 (2007).
8. Kirkali Z. Adverse events from targeted therapies in advanced renal cell carcinoma: the impact on long-term use. BJU Int. 107, 1722-1732 (2011).
9. Webber K, Cooper A, Kleiven H, Yip D, Goldstein D. Management of metastatic renal cell carcinoma in the era of targeted therapies. Intern. Med. J. 41, 594-605 (2011).
10. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36, 16-23 (2010).
11. Launay-Vacher V, Deray G. Hypertension and proteinuria: a class-effect of antiangiogenic therapies. Anticancer Drugs 20, 81-82 (2009).
12. Patel P, Srinivas S. Toxicities of targeted agents in advanced renal cell carcinoma. Curr. Clin. Pharmacol. 6(3), 181-188 (2011).
13. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
14. Escudier B, Albiges L. Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma. Drugs 71, 1179-1191 (2011).
15. Porta C, Paglino C, Imarisio I. Sorafenib rechallenge in metastatic renal cell carcinoma. BJU Int. (6 Pt B), E228-E234 (2012).
16. Albiges L, Lacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib in metastatic renal cell carcinoma: is there any active treatment? Eur. J. Cancer 47(Suppl. 1), Abstract 7143 (2011).
17. Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy. J. Clin. Oncol. 29(7 Suppl.), 305 (2011).
18. Busch J, Seidel C, Weikert S et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 11, 295 (2011).
19. Oudard S, Elaidi RT. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient beneft. Cancer Treat. Rev. 38(8), 981-987 (2012).
20. Sonpavde G, Choueiri TK, Escudier B, Ficarra V et al. Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur. Urol. 61, 307-316 (2012).
21. Porta C, Paglino C, Imarisio I, Ganini C, Pedrazzoli P. Immunological effects of multikinase inhibitors for kidney cancer: a clue for integration with cellular therapies? J. Cancer 2, 333-338 (2011).
22. Bracarda S, Ruggeri EM, Monti M et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit. Rev. Oncol. Hematol. 82(3), 378-386 (2012).
23. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 6, 491-500 (2005).
24. Manchen E, Robert C, Porta C. Management of tyrosine kinase inhibitor-induced hand-foot skin reaction: viewpoints from the medical oncologist, dermatologist, and oncology nurse. J. Support Oncol. 9, 13-23 (2011).
25. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reac tion with sorafenib: a systematic review and meta-analysis. Acta Oncol. 47, 176-186 (2008).
26. Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in pa tients with renal cell and non-renal cell carcinoma: a meta-ana lysis. Clin. Genitourin. Cancer 7, 11-19 (2009).
27. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastaticrenal-cellcarcinoma. N. Engl. J. Med. 356, 115-124 (2007).
28. Escudier B, Eisen T, Stadler WM et al. Sorafenib for treatment of renal cell carcinoma: fnal effcacy and safety results of the Phase III treatment approaches in renal cancer global evaluation trial. J. Clin. Oncol. 27, 3312-3318 (2009).
29. Sternberg C, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 28, 1061-1068 (2010).
30. Rini BI, Escudier B, Tomczak P. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet 378, 1931-1939 (2011).
31. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007).
32. Motzer RJ, Escudier B, Oudard S et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: fnal results and ana lysis of prognostic factors. Cancer 116 (18), 4256-4265 (2010).
33. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet 370 (9605), 2103-2111 (2007).
34. Boers-Doets CB, Epstein JB, Raber-Durlacher JE et al. Oral adverse events associated with tyrosine kinase and mammalian target of rapamycin inhibitors in renal cell carcinoma: a structured literature review. Oncologist 17, 135-144 (2012).
35. Melichar B, Koralewski P, Ravaud A et al. First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann. Oncol. 19, 1470-1476 (2008).
36. Di Lorenzo G, Autorino R, Bruni G et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter ana lysis. Ann. Oncol. 20, 1535-1542 (2009).
37. Ravaud A. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. Oncologist 16(Suppl. 2), 32-44 (2011).
38. Rini BI. Biomarkers: hypertension following anti-angiogenesis therapy. Clin. Adv. Hematol. Oncol. 8, 415-416 (2010).
39. Rini BI, Cohen DP, Lu DR et al. Hypertension as a biomarker of effcacy in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 103, 763-773 (2011).
40. Kim JJ, Vaziri SA, Rini BI et al. Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib. Cancer 118, 1946-5194 (2012).
41. Tolcher AW, Appleman LJ, Shapiro GI et al. A Phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother. Pharmacol. 67(4), 751-764 (2011).
42. Hurwitz HI, Saltz LB, Van Cutsem E et al. Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized Phase II and III studies. J. Clin. Oncol. 29(13), 1757-1764 (2011).
43. Ranpura V, Hapani S, Chuang J, Wu S. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-ana lysis of randomized controlled trials. Acta Oncol. 249(3), 287-297 (2010).
44. Hudes GR, Carducci MA, Choueiri TK et al. NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy. J. Natl Compr. Canc. Netw. 9, S1-S29 (2011).
45. White DA, Camus P, Endo M et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am. J. Respir. Crit. Care Med. 182, 396-403 (2010).
46. Dabydeen DA, Jagannathan JP, Ramaiya N et al. Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic fndings and correlation with clinical outcome. Eur. J. Cancer 48 (10), 1519-1524 (2012).
47. Agostino NM, Chinchilli VM, Lynch CJ et al. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice. J. Oncol. Pharm. Pract. 17, 197-202 (2011).
48. Mokhtari D, Welsh N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. Clin. Sci. 118, 241-247 (2010).
49. Templeton A, Brandle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann. Oncol. 19, 824-825 (2008).
50. Imarisio I, Paglino C, Ganini C, Magnani L, Caccialanza R, Porta C. The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma. Future Oncol. 8 (8), 1051-1057 (2012).
51. Wolter P, Stefan C, Decallonne B et al. The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br. J. Cancer 99, 448-454 (2008).
52. Rini BI, Tamaskar I, Shaheen P et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81-83 (2007).
53. Mueller EW, Rockey ML, Rashkin MC. Sunitinib-related fulminant hepatic failure: case report and review of the literature. Pharmacotherapy 28, 1066-1070 (2008).
54. Llovet JM, Ricci S, Mazzaferro V, Hilgard P et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378-390 (2008).
55. Bruix J, Raoul JL, Sherman M et al. Effcacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a Phase III trial. J. Hepatol. 57(4), 821-829 (2012).
56. Nieto M, Borregaard J, Ersboll J et al. The European medicines agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientifc assessment of the committee for medicinal products for human use. Clin. Cancer Res. 17, 6608-6614 (2011).
57. Di Lorenzo G, Porta C, Bellmunt J et al. Toxicities of targeted therapy and their management in kidney cancer. Kidney Cancer 59(4), e15-e26 (2011).
58. Escudier B, Gore M. Axitinib for the management of metastatic renal cell carcinoma. Drugs R D 11(2), 113-126 (2011).
59. Gross-Goupil M, Massard C, Ravaud A. Targeted therapies in metastatic renal cell carcinoma: overview of the past year. Curr. Urol. Rep. 13, 16-23 (2012).
60. Porta C, Bellmunt J, Eisen T, Szczylik C, Mulders P. Treating the individual: the need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat. Rev. 36, 16-23 (2010).
61. Di Fiore F, Rigal O, Ménager C, Michel P, Pfster C. Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib. Br. J. Cancer 105, 1811-1813 (2011).
62. Porta C, Szczylik C, Escudier B. Combination or sequencing strategies to improve the outcome of metastatic renal cell carcinoma patients: a critical review. Crit. Rev. Oncol. Hematol. 82(3), 323-337 (2012).
63. Srinivas S. Discussion of the oral abstract session. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium. Orlando, FL, USA, 14-16 February 2013.